- Abstract:
-
BACKGROUND: Guidelines recommend lopinavir/ritonavir (LPV/r) as first- and second-line therapy for young and older HIV-infected children, respectively. Available formulations have limitations making their widespread use complex. METHODS: An open-label comparative bioavailability (randomized crossover) study compared a novel twice-daily minitab sprinkle formulation (40 mg/10 mg, Cipla Pharmaceuticals) versus innovator syrup in HIV-infected Ugandan infants aged 3 to <12 months (cohort A) and...
Expand abstract - Publication status:
- Published
- Publisher:
- Lippincott Williams and Wilkins
- Journal:
- Journal of acquired immune deficiency syndromes (1999)
- Volume:
- 66
- Issue:
- 2
- Pages:
- 148-154
- Publication date:
- 2014-06-05
- DOI:
- EISSN:
-
1944-7884
- ISSN:
-
1525-4135
- URN:
-
uuid:00552868-0aae-4e46-8d97-043bd4163e75
- Source identifiers:
-
466264
- Local pid:
- pubs:466264
- Copyright date:
- 2014
Journal article
The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record